Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Ulrichts

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
The Journal of Clinical Investigation|July 25, 2018
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansPeter Ulrichts, Antonio Guglietta, Torsten Dreier, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Science Translational Medicine|September 18, 2024
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndromeRoeland Vanhauwaert, Julien Oury, Bernhardt Vankerckhoven, et al.
Iscience|February 3, 2025
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer modelsJamie L Lim, Stine Marie Jensen, Jaap J Plomp, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
The Lancet. Neurology|September 20, 2024
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trialJeffrey A Allen, Jie Lin, Ivana Basta, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Expert Review of Clinical Immunology|April 29, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseasesKelly G Gwathmey, Catherine M Broome, Matthias Goebeler, et al.
The Journal of Clinical Investigation|July 25, 2018
Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humansPeter Ulrichts, Antonio Guglietta, Torsten Dreier, et al.
American Journal of Hematology|December 11, 2019
Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopeniaAdrian C Newland, Blanca Sánchez-González, László Rejtő, et al.
Science Translational Medicine|September 18, 2024
ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndromeRoeland Vanhauwaert, Julien Oury, Bernhardt Vankerckhoven, et al.
Iscience|February 3, 2025
Patient-specific therapeutic benefit of MuSK agonist antibody ARGX-119 in MuSK myasthenia gravis passive transfer modelsJamie L Lim, Stine Marie Jensen, Jaap J Plomp, et al.
Neurology|May 24, 2019
Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravisJames F Howard, Vera Bril, Ted M Burns, et al.
The Lancet. Neurology|September 20, 2024
Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trialJeffrey A Allen, Jie Lin, Ivana Basta, et al.
Pageof 3